ES2690993T3 - Composiciones que contienen y métodos que implican derivados de dolastatina enlazados con aminoácidos no naturales y usos de los mismos - Google Patents

Composiciones que contienen y métodos que implican derivados de dolastatina enlazados con aminoácidos no naturales y usos de los mismos Download PDF

Info

Publication number
ES2690993T3
ES2690993T3 ES12793246.5T ES12793246T ES2690993T3 ES 2690993 T3 ES2690993 T3 ES 2690993T3 ES 12793246 T ES12793246 T ES 12793246T ES 2690993 T3 ES2690993 T3 ES 2690993T3
Authority
ES
Spain
Prior art keywords
alkylene
formula
nme
fifty
fifteen twenty
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12793246.5T
Other languages
English (en)
Inventor
Zhenwei Miao
Kyle C. ATKINSON
Sandra Biroc
Timothy BUSS
Melissa COOK
Vadim Kraynov
Robin MARSDEN
Jason Pinkstaff
Lillian SKIDMORE
Ying Sun
Angieszka SZYDLIK
Delia Ianina Lopez De Valenta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ambrx Inc
Original Assignee
Ambrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47259774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2690993(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ambrx Inc filed Critical Ambrx Inc
Application granted granted Critical
Publication of ES2690993T3 publication Critical patent/ES2690993T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from kidney or bladder cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compression Of Band Width Or Redundancy In Fax (AREA)
  • Polyamides (AREA)

Abstract

Un compuesto que tiene: **Fórmula** en donde: Z tiene la estructura de: **Fórmula** R5 es H, COR8, C1-C6 alquilo o tiazol; R8 es OH o -NH-(alquileno-O)n-NH2; R6 es OH o H; Ar es fenilo o piridina; R7 es C1-C6 alquilo o hidrógeno; Y se selecciona del grupo que consiste en una hidroxilamina; L es un enlazador seleccionado del grupo que consiste en -alquileno-, -alquileno-C(O)-, -(alquileno-O)n-alquileno-, - (alquileno-O)n-alquileno-C(O)-, -(alquileno-O)n- (CH2)n'-NHC(O)-(CH2)n"-C(Me)2-S-S-(CH2)n'"-NHC(O)-(alquileno-O)n''''- alquileno-, -(alquileno-O)n-alquileno-W-, -alquileno-C(O)-W-, -(alquileno-O)n-alquileno-U-alquileno-C(O)- y - (alquileno-O)n-alquileno-U-alquileno-; W tiene la estructura de: **Fórmula** U tiene la estructura de: **Fórmula** o L está ausente, Y es metilo, R5 es COR8, y R8 es -NH-(alquileno-O)n-NH2; y cada n, n', n", n'" y n"" son independientemente enteros mayores que o iguales a uno; o una sal del mismo; (ii) Fórmula (III), (IV), (V) o (VI):**Fórmula** en donde: Z tiene la estructura de: **Fórmula** R5 es H, COR8, C1-C6 alquilo o tiazol; R8 es OH; R6 es OH o H; Ar es fenilo o piridina; R7 es C1-C6 alquilo o hidrógeno; Y y V se seleccionan cada uno del grupo que consiste en una hidroxilamina; L1, L2, L3 y L4 son cada uno de los enlazadores seleccionados independientemente del grupo que consiste en un enlace, -alquileno-, -(alquileno-O)n-alquileno-J-, -alquileno'-J-(alquileno-O)n-alquileno-, -J-(alquileno-O)n-alquileno-, - (alquileno-O)n-alquileno-J-(alquileno-O)n'-alquileno-J'-, -(alquileno-O)n-alquileno-J-alquileno'-, -W-, -alquileno-W-, alquileno'-J-(alquileno-NMe)n-alquileno-W-, -J-(alquileno-NMe)n-alquileno-W-, -J-alquileno-NMe-alquileno'-NMe- alquileno"-W-, y -alquileno-J-alquileno'-NMe-alquileno"-NMe-alquileno"'-W-; W tiene la estructura de: **Fórmula** cada J y J' tienen independientemente la estructura de: **Fórmula** y cada n y n' son independientemente enteros mayores que o iguales a uno; o una sal del mismo.

Description

5
10
15
20
25
30
35
40
45
50
55
60
65
DESCRIPCIÓN
Composiciones que contienen y métodos que implican derivados de dolastatina enlazados con aminoácidos no naturales y usos de los mismos
ANTECEDENTES DE LA INVENCIÓN
[0001] La capacidad de incorporar aminoácidos no genéticamente codificados (es decir, "aminoácidos no naturales") en proteínas permite la introducción de grupos funcionales químicos que podrían proporcionar alternativas valiosas a los grupos funcionales naturales, tales como el épsilon -NH2 de lisina, el sulfhidrilo -SH de cisteína, el grupo imino de histidina, etc. Se sabe que ciertos grupos funcionales químicos son inertes a los grupos funcionales que se encuentran en los 20 aminoácidos codificados genéticamente, pero que reaccionan limpia y eficientemente para formar enlaces estables con grupos funcionales que pueden incorporarse a aminoácidos no naturales.
[0002] Los métodos ahora están disponibles para introducir selectivamente grupos funcionales químicos que no se encuentran en las proteínas, que son químicamente inertes a todos los grupos funcionales encontrados en los 20 aminoácidos genéticamente codificados, y que pueden usarse para reaccionar de manera eficiente y selectivamente con reactivos que comprenden ciertos grupos funcionales para formar enlaces covalentes estables.
Los documentos WO 03/043583 A2 y WO 2004/073656 A2 describen métodos para el tratamiento de trastornos inmunológicos usando anticuerpos anti-CD30. El documento WO 2004/073656 A2 describe conjugados de anticuerpo y fármaco de PSMA. El documento US 2009/047296 A1 describe conjugados de ligando de auristatina.
SUMARIO DE LA INVENCIÓN
[0003] En este documento, se describen restos tóxicos con uno o más engarce(s), grupos tóxicos unidos a aminoácidos no naturales y procedimientos para preparar tales aminoácidos y polipéptidos no naturales.
[0004] La presente invención describe un compuesto, o una sal del mismo, que comprende la Fórmula (I):
imagen1
en donde:
Z tiene la estructura de:
imagen2
R5 es H, CORa, C1-C6 alquilo o tiazol;
Re es OH o -NH-(alquileno-O)n-NH2;
R6 es OH o H;
Ar es fenilo o piridina;
R7 es C1-C6 alquilo o hidrógeno;
Y se selecciona del grupo que consiste en una hidroxilamina;
L es un engarce seleccionado del grupo que consiste en -alquileno-, -alquileno-C(O)-, -(alquileno-O)n-alquileno-, - (alquileno-O)n-alquileno-C(O)-, -(alquileno-O)n-(CH2)n'-NHC(O)-(CH2)n"-C(Me)2-S-S-(CH2)n'"-NHC(O)-(alquileno-
O)n""-alquileno-, -(alquileno-O)n-alquileno-W-, -alquileno-C(O)-W-, -(alquileno-O)n-alquileno-U-alquileno-C(O)-, y - (alquileno-O)n-alquileno-U-alquileno-;
W tiene la estructura de:
5
10
15
20
25
30
35
40
45
50
55
60
65
imagen3
U tiene la estructura de:
imagen4
o L está ausente, Y es metilo, R5 es COR8, y R8 es -NH-(alquileno-O)n-NH2; y cada n, n', n”, n'" y n”” son independientemente enteros mayores que o iguales a uno.
[0005] En algunas realizaciones, R5 es tiazol. En otras realizaciones, R6 es H. En ciertas realizaciones, Ar es fenilo. En realizaciones adicionales o adicionales, R7 es metilo. En algunas realizaciones, n es un número entero de 0 a 20, de 0 a 10 o de 0 a 5.
[0006] En algunas realizaciones, se describe un compuesto que comprende la Fórmula (II):
imagen5
En ciertas realizaciones, L es -(alquileno-O)n-alquileno-. En realizaciones específicas, cada alquileno es -CH2CH2-, n es igual a 3, y R7 es metilo. En otras realizaciones, L es -alquileno-. En realizaciones específicas, cada alquileno es - CH2CH2- y R7 es metilo o hidrógeno. En ciertas realizaciones, L es -(alquileno-O)n-alquileno-C(O)-. En ciertas realizaciones específicas, cada alquileno es -CH2CH2-, n es igual a 4, y R7 es metilo. En realizaciones adicionales o alternativas, L es -(alquileno-O)n-(CH2)n'-NHC(O)-(CH2)n”-C(Me)2-S-S-(CH2)n”-NHC(O)-(alquileno-O)n'-alquileno-. En realizaciones específicas, cada alquileno es -CH2CH2-, n es igual a 1, n' es igual a 2, n” es igual a 1, n"' es igual a 2, n”” es igual a 4, y R7 es metilo. La presente invención también describe un compuesto, o una sal del mismo, que comprende la Fórmula (III), (IV), (V) o (VI):

Claims (8)

  1. 5
    10
    15
    20
    25
    30
    35
    40
    45
    50
    55
    60
    65
    1. Un compuesto que tiene: (i) Fórmula (I):
    imagen1
    en donde:
    Z tiene la estructura de:
    imagen2
    R5 es H, COR8, C1-C6 alquilo o tiazol;
    R8 es OH o -NH-(alquileno-O)n-NH2;
    R6 es OH o H;
    Ar es fenilo o piridina;
    R7 es C1-C6 alquilo o hidrógeno;
    Y se selecciona del grupo que consiste en una hidroxilamina;
    L es un enlazador seleccionado del grupo que consiste en -alquileno-, -alquileno-C(O)-, -(alquileno-O)n-alquileno-, - (alquileno-O)n-alquileno-C(O)-, -(alquileno-O)n- (CH2)n'-NHC(O)-(CH2)n"-C(Me)2-S-S-(CH2)n'"-NHC(O)-(alquileno-O)n— alquileno-, -(alquileno-O)n-alquileno-W-, -alquileno-C(O)-W-, -(alquileno-O)n-alquileno-U-alquileno-C(O)- y -
    (alquileno-O)n-alquileno-U-alquileno-;
    W tiene la estructura de:
    imagen3
    U tiene la estructura de:
    imagen4
    o L está ausente, Y es metilo, R5 es COR8, y R8 es -NH-(alquileno-O)n-NH2; y cada n, n', n”, n'" y n”” son independientemente enteros mayores que o iguales a uno;
    5
    10
    15
    20
    25
    30
    35
    40
    45
    50
    55
    60
    65
    o una sal del mismo;
    (ii) Fórmula (III), (IV), (V) o (VI):
    imagen5
    imagen6
    5
    10
    15
    20
    25
    30
    35
    40
    45
    50
    55
    60
    65
    imagen7
    imagen8
    en donde:
    Z tiene la estructura de:
    imagen9
    R5 es H, COR8, C1-C6 alquilo o tiazol;
    R8 es OH;
    R6 es OH o H;
    Ar es fenilo o piridina;
    R7 es C1-C6 alquilo o hidrógeno;
    Y y V se seleccionan cada uno del grupo que consiste en una hidroxilamina;
    L1, L2, L3 y L4 son cada uno de los enlazadores seleccionados independientemente del grupo que consiste en un enlace, -alquileno-, -(alquileno-O)n-alquileno-J-, -alquileno'-J-(alquileno-O)n-alquileno-, -J-(alquileno-O)n-alquileno-, - (alquileno-O)n-alquileno-J-(alquileno-O)n-alquileno-J'-, -(alquileno-O)n-alquileno-J-alquileno'-, -W-, -alquileno-W-, alquileno'-J-(alquileno-NMe)n-alquileno-W-, -J-(alquileno-NMe)n-alquileno-W-, -J-alquileno-NMe-alquileno'-NMe-
    5
    10
    15
    20
    25
    30
    35
    40
    45
    50
    55
    60
    65
    alquileno”-W-, y -alquileno-J-alquileno-NMe-alquileno”-NMe-alquileno”'-W-; W tiene la estructura de:
    imagen10
    cada J y J' tienen independientemente la estructura de:
    imagen11
    o
    imagen12
    y
    cada n y n' son independientemente enteros mayores que o iguales a uno; o una sal del mismo
  2. 2. El compuesto de la reivindicación 1 que tiene la Fórmula (I), o una sal del mismo.
  3. 3. El compuesto de cualquier reivindicación precedente que tiene la Fórmula (I), (III) o (V), donde R5 es tiazol o ácido carboxílico.
  4. 4. El compuesto de cualquier reivindicación precedente que tiene la Fórmula (I), (III) o (V), en donde Ar es fenilo.
  5. 5. El compuesto de cualquier reivindicación precedente en el que cada alquileno, alquileno', alquileno'' y alquileno''
    es independientemente -CH2-, -CH2CH2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, -CH2CH2CH2CH2CH2-, -
    CH2CH2CH2CH2CH2CH2-, -CH2CH2CH2CH2CH2CH2CH2-, -CH2CH2CH2CH2CH2CH2CH2CH2-, -
    CH2CH2CH2CH2CH2CH2CH2CH2CH2-, -CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2-, -
    CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2-, o -CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2-.
  6. 6. El compuesto de cualquiera de las reivindicaciones precedentes en el que la Fórmula (I) es:
    5
    10
    15
    20
    25
    30
    35
    40
    45
    50
    55
    60
    65
    imagen13
    imagen14
    imagen15
    imagen16
    imagen17
    imagen18
    imagen19
    imagen20
    5
    10
    15
    20
    25
    30
    35
    40
    45
    50
    55
    60
    65
    imagen21
    5
    10
    15
    20
    25
    30
    35
    40
    45
    50
    55
    60
    65
    imagen22
    5
    10
    15
    20
    25
    30
    35
    40
    45
    50
    55
    60
    65
    imagen23
    ; o
    imagen24
  7. 7. El compuesto de cualquiera de las reivindicaciones anteriores en el que la Fórmula (I) es:
    imagen25
    imagen26
    a
    o □ a a
    2 a. 1 |
    Z-
    CN
    □
    □
    m ■
    imagen27
    o_
    LV205
    LK145
    HS163
    HE272
    HK329
    HN289
    HH288
    HK217
    HK213
    HN211
    HT200
    HS122
    HA121
    wt
    FIG. 2
    147
    C
    ~9
    a
    K
    c
    ra
    T.
    EZE5? Z
    imagen28
    HS163
    HE272
    HK329
    HN289
    HK288
    HK217
    HK213
    HN211
    HT200
    HS122
    HA121
    wt
    en
    E
    Q.
    FIG. 3
    148
    % de control de medio
    Ensayo de proliferación HCC1953 enlazador de dolastatina 100810, IV
    imagen29
    1e-5 1e-4 1e-3 1e-2 1e-1 1e+0 1e*1 1e*2 1e+3
    log[nM]
    • Dolastatina (fármaco libre) CI50=0,04nM R2=0,9951 Q WT hier vs Her ▼ NCL-D1 Ci50<0.01nM v NCL D-2 Ci5O<0,0lnM ■ PHC-D-2 Ci50=2nM R2=0.9981
    imagen30
    Ensayo de proliferación HCC1954
    Conjugados de Herx-tox, 100810, IV
    imagen31
    100 -
    60
    40
    20
    1000
    0,0001
  8. 0.001
    logfnM]
    Doas;a:na ífarmaco libre} CI5Q=0.07nM RZ-Q.9S59
    WT Her vs WT Herceplm
    4D5-A121 NCL D-1 CiSO-0 15nM R2=0,9990
    4D5-A121-l\ICL-D-2 Cl5ü=0 n.nM R2=0.9937
    V
    4D&-A121-PHC-D-2Ci50=0.12nM R2=O.9980
    F G. 5
    % de corirgl ce medio
    Ensayo de proliferación SKOV3
    imagen32
    logfnMJ
    • Dolastaüna [fármaco libre)CI5C=Ü. 15nM R2=0,9954 o WT Herceptin IC50=>300nM ▼ NC-D-1 ci5D<o inM v NL O'2Ci5C=0.08nM R2=0-9830'
    ■ PHC-D-2Ci50=8nM R2=0 9970
    FIG.6
    %■ de control cíe medio
    Ensayo de proliferación SKOV3 Conjugados Her-tox 101210 IV
    imagen33
    0,0001 0 001 0,01 0,1 1 10 100 1000
    log[rM]
    • Dolasiatina (fármaco libre] CI5Q-Q.2pM R2=Q,993& O WT Herceptin IC50=>30ÜnM ▼ 4D5-A121-NCL-D-1 Ci50=1 3nM R2=0.9987
    v 4D5-A121-NCL-D 2 CI50=1,3,nM R2=0.9287*
    ■ 4D5-A121 -PHC-D-2 C i5ü=Q,3nM R2=0.9992
    FIG. 7
    % de control de medio
    Ensayo de proliferación MDA-MB-468 Enlazador de dolastatina 100810, IV
    imagen34
    1e-5 1e4 1e-3 1e-2 1e-1 1e+0 1e+1 1e+2 1e+3
    log[nM]
    • Dolasiatinú (fármaco libro) *0,01 nM o WTHercept¡nci5O=>300nM v NCL-D-1 ciso <Q.1nM ▼ NCL-D2 ciso=0r3nM R2=0.9438
    ■ PHC-D2 CI&0=1.6nM R2=Ü,9984
    FIG. 8
    % de control de medio
    Ensayo de proliferación MDA-MB-468 Conjugados de Her-tox, 100810, IV
    imagen35
    1e-5 1M 1e-3 1e-2 1e-1 1e+0 ie+1 1e+2 ie+3
    log[nM]
    • Doiasiatina (fármaco I ib reí
    o WT Herceplin >3ÜGnM
    v 4D5-A121-NC-D1 ci5Cs >10GnM
    t 405-A121-NC D2 Ci50= >1 OOnM
    ■ 4D5-A121-PHC-D2 ci5t=5.SnM R2=Ü,9882'
    FIG. 9
    imagen36
    vahííütc IV un* íti
    trastuiumab 3 3 nrtg.'kg trasUizumab 10 mg/ng * trastuzuroab20 mgkg
    Her-HS123-MC1D3.3 miyKj -o- hef-HS1?MJClDl0nts/k5 her-HS12MClD2Dmc/kg Her-HS122/LK WS HC ‘ 0 3 3 mg/kg her-HS12^LK‘4GHC1D10mgjVg ^ h er-HS122/LK145- H C ‘ D 20 mg.kg -*■ pací laxe 25 mgfcg V qo<Jx5
    —l
    35
    imagen37
    Formatos do ensayo utilizados para medirla concentración do dorivado do dolastatina ligada a HER2 on suero do ratón dolastatina do molócula pequera (SM)
    imagen38
    Aplicación:
    •Perfil PK para HER2 SM •Ab na conjugado •Ab conjugado
    imagen39
    Conc. do su oro {ng/mL) Conc. do suero {ngJmL]
    imagen40
    imagen41
    imagen42
    hora* Ir» InyéítiÓrt IV únk*
    ♦ HER-HS122-NC10
    * HER-HS122-HC1D
    HER-HS122-PHC?D
    HER-HA121-NC1D
    HER-HA121-HC1D
    imagen43
    158
    100000 10000
    Conc. do guaro <
    (ng/mL) 1000 100
    10 t 1 t 1 T 1
    0 100 200 300 400 600
    horas tras Inyección IV única
    imagen44
    HER-HS122-NC1D HER-HS122-HC1D HER-HS122-PHC2D ■W- HER-HS122ÍLK145-NC1D HER-H$122fl_K145-HC1D ^ HER-HA121-NC1D -B- HER-HA121-NC1D
    FIG. 13
    Cnnc. ¡Ir sunrn (ng.'rrl.)
    imagen45
    Pma mrpnrtl (g)
    Datos de resumen medios de grupo HCC1954-e202 (TV = 1.000 mm3 o Día 60)
    imagen46
    imagen47
    Vorucuio IV una ve2
    trastuzumab 3.3 mgkg
    trastuzumab 10 mg/kg
    trastuzumab 20 mg/kg
    HS122-NC1D 3 3 mg/kg
    Volumen 400 -
    HS122-NCID 10 mg/kg
    tumora
    (mm’l
    HS122-NC1D 20 mg/kg
    HS122/LK145-HC1D 3 3 mg/kg
    HS122/LK145-HC1D 10 mg/kg
    200 -
    HS122/LK145-HC1D 20 mg/kg
    paclitaxel 25 mg/kg IV qodx5
    Días iras dosis iv única en el día i
    FIG. 16
    Ve lumen
    Mama MDA361DYT2 (2+)
    imagen48
    Da
    Ver (culo
    -o- AmbotAI NC Di lOng/kg Ambot A1-NC*D*1 3 rngrttg -4- AubncAl-NC'tM 1 mgAg Al mcMWAD 10 nig/kg _cv A1 mcMWAD 3 mg^g Al mcMMAF 1 mgAg A1 mcMMAF 10 mg/kg
    imagen49
    imagen50
    '500
    Vehículo
    121NCMJ1 lümgrt.g
    1000
    121NC-D1 3 mufla
    121NC-D1 1 oiQKQ
    AlncMMAJ 10 mg/kg
    AlmcMMA j 3 rng/M
    AlntiMMAj 1 mqíkg
    500
    A1ndMMAr lOngflig
    AlncMMA- 3 mgAc
    □ j
    FG. 18
    Modelo de xenoinjerto de Mama MDA361DYT2 (2+)
ES12793246.5T 2011-05-27 2012-05-24 Composiciones que contienen y métodos que implican derivados de dolastatina enlazados con aminoácidos no naturales y usos de los mismos Active ES2690993T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161491146P 2011-05-27 2011-05-27
US201161491146P 2011-05-27
PCT/US2012/039472 WO2012166560A1 (en) 2011-05-27 2012-05-24 Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives

Publications (1)

Publication Number Publication Date
ES2690993T3 true ES2690993T3 (es) 2018-11-23

Family

ID=47259774

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12793246.5T Active ES2690993T3 (es) 2011-05-27 2012-05-24 Composiciones que contienen y métodos que implican derivados de dolastatina enlazados con aminoácidos no naturales y usos de los mismos

Country Status (23)

Country Link
US (4) US9796754B2 (es)
EP (2) EP2714684B1 (es)
JP (5) JP6581774B2 (es)
KR (4) KR102356286B1 (es)
CN (4) CN103717595A (es)
AU (4) AU2012262560B2 (es)
BR (1) BR112013030372A2 (es)
CA (1) CA2837586C (es)
CL (1) CL2013003406A1 (es)
CO (1) CO6811816A2 (es)
CR (1) CR20130667A (es)
DK (1) DK2714684T3 (es)
EA (1) EA201391756A1 (es)
EC (1) ECSP13013115A (es)
ES (1) ES2690993T3 (es)
GT (1) GT201300295A (es)
IL (3) IL229505A (es)
MX (1) MX359217B (es)
NI (1) NI201300130A (es)
PE (1) PE20140784A1 (es)
PH (1) PH12013502461A1 (es)
WO (1) WO2012166560A1 (es)
ZA (1) ZA201309654B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA34521B1 (fr) 2010-08-17 2013-09-02 Ambrx Inc Polypeptides de relaxine modifiés et leurs utilisations
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
KR102356286B1 (ko) * 2011-05-27 2022-02-08 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
KR20140037105A (ko) * 2011-05-27 2014-03-26 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
US20130190248A1 (en) * 2011-07-26 2013-07-25 Agensys, Inc. Substituted peptide analogs
US9981046B2 (en) 2012-05-15 2018-05-29 Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. Drug-conjugates, conjugation methods, and uses thereof
US10800856B2 (en) * 2012-06-07 2020-10-13 Ambrx, Inc. Prostate-specific membrane antigen antibody drug conjugates
SG11201408494UA (en) * 2012-06-19 2015-02-27 Ambrx Inc Anti-cd70 antibody drug conjugates
US10226535B2 (en) 2012-12-10 2019-03-12 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
CN105283201B (zh) 2013-03-14 2019-08-02 斯克利普斯研究所 靶向剂抗体偶联物及其用途
EP2968591A1 (en) * 2013-03-15 2016-01-20 Novartis AG Cell proliferation inhibitors and conjugates thereof
PL2968440T3 (pl) 2013-03-15 2019-12-31 Zymeworks Inc. Związki cytotoksyczne i antymitotyczne oraz sposoby ich stosowania
FR3005051A1 (fr) * 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
PL2991683T3 (pl) * 2013-05-02 2020-03-31 Glykos Finland Oy Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem
KR102339240B1 (ko) 2013-10-15 2021-12-15 더 스크립스 리서치 인스티튜트 펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도
ES2826398T3 (es) 2013-10-15 2021-05-18 Seagen Inc Enlazadores-fármacos pegilados para una mejor farmacocinética de los conjugados ligando-fármaco
WO2015057876A1 (en) 2013-10-15 2015-04-23 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
CN103665104B (zh) * 2013-12-09 2015-05-20 天津市康信医药科技有限公司 一种mmaf中间体五肽的合成方法
BR112016012538A2 (pt) 2013-12-17 2017-09-26 Novartis Ag peptídeos citotóxicos e conjugados dos mesmos
RU2729194C2 (ru) 2013-12-27 2020-08-05 Займворкс Инк. Сульфонамидсодержащие связывающие системы для лекарственных конъюгатов
RU2692563C2 (ru) 2014-04-25 2019-06-25 Пьер Фабр Медикамент Конъюгат антитела против igf-1r с лекарственным средством и его применение для лечения рака
BR112016024363A2 (pt) 2014-04-25 2017-10-10 Pf Medicament conjugado de anticorpo-fármaco e seu uso para tratamento de câncer
CN106573956A (zh) 2014-06-13 2017-04-19 诺华股份有限公司 澳瑞他汀衍生物及其缀合物
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
AU2015318556C1 (en) 2014-09-17 2021-01-07 Zymeworks Bc Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
MX2017007169A (es) 2014-12-03 2018-05-02 Genentech Inc Compuestos de amina cuaternaria y conjugados de anticuerpofármaco de los mismos.
EP3250238B1 (en) 2015-01-28 2022-06-01 Sorrento Therapeutics, Inc. Antibody drug conjugates
ES2884844T3 (es) 2015-03-09 2021-12-13 Agensys Inc Conjugados de anticuerpo fármaco (ADC) que se unen a proteínas FLT3
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
WO2016168773A2 (en) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
CN105949277B (zh) * 2015-05-05 2019-03-01 成都永泰诺科技有限公司 一种抗肿瘤化合物及其用途
JP6486316B2 (ja) 2015-11-03 2019-03-20 財團法人工業技術研究院Ｉｎｄｕｓｔｒｉａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗体−薬物複合体（ａｄｃ）およびそれを形成するための方法
AU2017213886B2 (en) 2016-02-04 2024-03-07 The California Institute For Biomedical Research Humanized anti-CD3 antibodies, conjugates and uses thereof
EP3423105B1 (en) 2016-03-02 2021-05-05 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
KR20180134351A (ko) 2016-03-25 2018-12-18 시애틀 지네틱스, 인크. 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
CN110267982B (zh) 2016-10-19 2024-02-23 斯克利普斯研究所 具有人源化靶向部分和/或经过优化的嵌合抗原受体相互作用结构域的嵌合抗原受体效应细胞开关以及其用途
CN110637027B (zh) 2017-02-08 2024-08-30 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
AU2018237683A1 (en) 2017-03-24 2019-10-31 Seagen Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
MX2020004691A (es) 2017-11-07 2020-08-20 Regeneron Pharma Enlazadores hidrofilicos para conjugados anticuerpo-farmaco.
CN111417408B (zh) * 2017-11-30 2024-04-23 思进公司 药物接头化合物的制备方法
US12059473B2 (en) 2018-03-29 2024-08-13 Ambrx, Inc. Humanized anti-prostate -specific membrane antigen (PSMA) antibody drug conjugates
CA3103265A1 (en) 2018-06-12 2019-12-19 Angiex, Inc. Antibody-oligonucleotide conjugates
CN109232712B (zh) * 2018-08-21 2021-08-03 联宁（苏州）生物制药有限公司 一种用于抗体药物偶联物的中间体的制备方法
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
WO2020047176A1 (en) 2018-08-28 2020-03-05 Ambrx, Inc. Anti-cd3 antibody folate bioconjugates and their uses
JP7695885B2 (ja) 2019-02-12 2025-06-19 アンブルックス，インコーポレイテッド 抗体－ｔｌｒアゴニストコンジュゲートを含有する組成物、その方法、及び使用
US12428477B2 (en) 2019-02-27 2025-09-30 Angiex, Inc. Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same
WO2021032933A1 (en) * 2019-08-21 2021-02-25 Kalvista Pharmaceuticals Limited Enzyme inhibitors
WO2021066869A1 (en) 2019-10-04 2021-04-08 TAE Life Sciences Antibody compositions comprising fc mutations and site-specific conjugation properties
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
US20230022596A1 (en) * 2021-06-18 2023-01-26 Clarence Hurt Neoantigen-eliciting antibody drug conjugates for the immunotherapy of cancer
US20240245609A1 (en) * 2021-07-20 2024-07-25 Novocodex Biopharmaceuticals Co., Ltd. Freeze-dried composition containing anti-her2 drug conjugate, freeze-dried preparation and preparation method therefor and use thereof
MX2024002571A (es) 2021-09-03 2024-03-20 Toray Industries Composicion farmaceutica para tratamiento y/o prevencion de cancer.
JP2025535713A (ja) 2022-10-07 2025-10-28 アンブレツクス・インコーポレイテツド 薬物リンカー及びその抗体コンジュゲート
AU2024209360A1 (en) 2023-01-16 2025-09-04 Ambrx, Inc. Anti-cd70 antibody-drug conjugates
WO2024178310A1 (en) 2023-02-23 2024-08-29 Ambrx, Inc. Trop2-directed antibody-drug conjugates and uses thereof
WO2024241086A1 (en) 2023-05-24 2024-11-28 Ambrx, Inc. Pegylated bovine interferon lambda and methods of use thereof
EP4727971A1 (en) 2023-06-13 2026-04-22 Adcentrx Therapeutics Inc. Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
IL326709A (en) 2023-08-22 2026-04-01 Ambrx Inc Anti-PSMA ADC conjugate compositions and methods of using them
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN118754934B (zh) * 2024-06-05 2025-02-07 浙江新码生物医药有限公司 一种用于制备药物偶联物的毒素衍生物
WO2025264533A1 (en) 2024-06-17 2025-12-26 Adcentrx Therapeutics Inc. Methods and compositions related to antibody drug conjugates (adcs) that bind steap-1 proteins
WO2025262641A1 (en) 2024-06-19 2025-12-26 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
EP0188256B1 (en) 1985-01-14 1991-08-21 NeoRx Metal radionuclide labeled proteins for diagnosis and therapy
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5831002A (en) 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
US5635483A (en) * 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US6034065A (en) * 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5599902A (en) * 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
JP2002505338A (ja) 1998-03-05 2002-02-19 カイロン コーポレイション 生物学的に活性な分子の血清半減期を増加するための方法
KR20020022691A (ko) * 1999-06-08 2002-03-27 와이즈먼 앤드루 아미노옥시기를 포함하는 원자가 플랫폼 분자
US6323315B1 (en) * 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
BR0111726A (pt) 2000-06-16 2003-05-27 Mitra Medical Technology Ab Derivados de biotina
US7083970B2 (en) 2001-04-19 2006-08-01 The Scripps Research Institute Methods and compositions for the production of orthogonal tRNA-aminoacyl tRNA synthetase pairs
US6649402B2 (en) 2001-06-22 2003-11-18 Wisconsin Alumni Research Foundation Microfabricated microbial growth assay method and apparatus
US6737409B2 (en) * 2001-07-19 2004-05-18 Hoffmann-La Roche Inc. Dolastatin 10 derivatives
CA2467242A1 (en) 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
SI1545613T1 (sl) * 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
WO2004058946A2 (en) 2002-12-22 2004-07-15 The Scripps Research Institute Protein arrays
AU2004213053C1 (en) 2003-02-20 2009-07-16 Seagen Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US7498298B2 (en) * 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
CA2567914A1 (en) * 2004-06-02 2005-12-15 F. Hoffmann-La Roche Ag Synthesis of amino-alkoxy-heptanoic alkyl ester
DK1812031T3 (en) 2004-11-01 2015-09-14 Univ California Compositions and methods for the modification of biomolecules
NZ565075A (en) * 2005-06-20 2011-05-27 Psma Dev Company Llc PSMA antibody-drug conjugates
CN104710503B (zh) 2005-11-08 2023-04-25 Ambrx 公司 用于修饰非天然氨基酸和非天然氨基酸多肽的促进剂
US7750116B1 (en) * 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
EP2265283B1 (en) * 2008-03-18 2014-09-03 Seattle Genetics, Inc. Auristatin drug linker conjugates
WO2010111018A1 (en) * 2009-03-06 2010-09-30 Agensys, Inc. Antibody drug conjugates (adc) that bind to 24p4c12 proteins
MX2011010265A (es) * 2009-04-01 2011-10-11 Genentech Inc Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso.
US8521087B2 (en) 2009-07-15 2013-08-27 Lg Electronics Inc. System and method for cognitive radio transmission
WO2011038159A2 (en) * 2009-09-24 2011-03-31 Seattle Genetics, Inc. Dr5 ligand drug conjugates
WO2011058188A1 (en) * 2009-11-16 2011-05-19 Centre National De La Recherche Scientifique - Cnrs - Compounds and methods for purifying peptides produced by solid phase peptide synthesis
HUE045348T2 (hu) * 2011-05-08 2019-12-30 Legochem Biosciences Inc Fehérje-hatóanyag konjugátumok és eljárás elõállításukra
KR20140037105A (ko) 2011-05-27 2014-03-26 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
KR102356286B1 (ko) 2011-05-27 2022-02-08 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도

Also Published As

Publication number Publication date
JP2014516050A (ja) 2014-07-07
GT201300295A (es) 2014-11-24
KR102356286B1 (ko) 2022-02-08
US11420999B2 (en) 2022-08-23
AU2012262560B2 (en) 2016-06-09
KR20210106023A (ko) 2021-08-27
PE20140784A1 (es) 2014-07-03
KR20140028073A (ko) 2014-03-07
JP2018109033A (ja) 2018-07-12
WO2012166560A1 (en) 2012-12-06
JP2024170587A (ja) 2024-12-10
MX2013013683A (es) 2014-01-08
ZA201309654B (en) 2016-08-31
CN110078787A (zh) 2019-08-02
CL2013003406A1 (es) 2014-07-25
JP2020147587A (ja) 2020-09-17
AU2018203639B2 (en) 2020-05-14
CO6811816A2 (es) 2013-12-16
US20180009845A1 (en) 2018-01-11
CN110078788A (zh) 2019-08-02
EP2714684B1 (en) 2018-09-05
CN113527414A (zh) 2021-10-22
US9796754B2 (en) 2017-10-24
IL274204B (en) 2022-03-01
US20160052966A1 (en) 2016-02-25
JP6581774B2 (ja) 2019-09-25
AU2016204454A1 (en) 2016-07-21
EP2714684A1 (en) 2014-04-09
IL254879B (en) 2020-05-31
EP3470413A2 (en) 2019-04-17
US20210277056A1 (en) 2021-09-09
ECSP13013115A (es) 2014-06-30
AU2020217337B2 (en) 2022-11-17
IL274204A (en) 2020-06-30
CA2837586A1 (en) 2012-12-06
CR20130667A (es) 2014-03-12
JP2023002671A (ja) 2023-01-10
AU2016204454B2 (en) 2018-03-01
MX359217B (es) 2018-09-19
NZ618079A (en) 2016-04-29
US10954270B2 (en) 2021-03-23
US20220411469A1 (en) 2022-12-29
AU2018203639A1 (en) 2018-06-14
JP7638942B2 (ja) 2025-03-04
EA201391756A1 (ru) 2014-05-30
IL229505A (en) 2017-10-31
PH12013502461A1 (en) 2017-08-09
AU2020217337A1 (en) 2020-08-27
EP3470413A3 (en) 2019-08-07
KR102179369B1 (ko) 2020-11-16
IL229505A0 (en) 2014-01-30
KR20200128601A (ko) 2020-11-13
IL254879A0 (en) 2017-12-31
AU2012262560A1 (en) 2013-05-09
KR20190115109A (ko) 2019-10-10
EP2714684A4 (en) 2015-04-08
JP6781721B2 (ja) 2020-11-04
CN110078788B (zh) 2021-08-06
CA2837586C (en) 2018-12-11
BR112013030372A2 (pt) 2016-08-30
NI201300130A (es) 2014-12-22
DK2714684T3 (en) 2018-11-26
CN103717595A (zh) 2014-04-09
KR102030856B1 (ko) 2019-10-10

Similar Documents

Publication Publication Date Title
ES2690993T3 (es) Composiciones que contienen y métodos que implican derivados de dolastatina enlazados con aminoácidos no naturales y usos de los mismos
Yang et al. Tumor‐specific peroxynitrite overproduction disrupts metabolic homeostasis for sensitizing melanoma immunotherapy
Lee et al. The comparative immunotoxicity of mesoporous silica nanoparticles and colloidal silica nanoparticles in mice
JP7784899B2 (ja) 高速で且つ効率的なクリック放出の為の化合物
JP5739880B2 (ja) ＩｇＧ結合のための部位を同定するための方法
BR112020002368A2 (pt) conjugados anticorpo-medicamento tendo alta tolerabilidade in vivo
ES2688726T3 (es) Métodos y formulaciones que permiten la modulación de respuestas inmunitarias relacionadas con la administración de un fármaco biofarmacéutico
BR112020010405A2 (pt) compostos conjugado conectado à cadeia lateral e de conexão de cadeia lateral, cadeias laterais q1 e q2, d (estrutura de tubulisina), w, l1, l2, v1 e v2, agente/molécula de ligação de célula, célula de tumor, composição farmacêutica, e, agentes quimioterapêutico e sinergísticos
Gibbens-Bandala et al. Synthesis and evaluation of 177Lu-DOTA-DN (PTX)-BN for selective and concomitant radio and drug—therapeutic effect on breast cancer cells
EP2846842A1 (en) Radio-pharmaceutical complexes
BR112021023501A2 (pt) Formulações estabilizadas contendo anticorpos anti-angptl3
BR112013002764A2 (pt) formulações esatabilizadas contendo anticorpos anti-ngf.
DOP2012000193A (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r)
JP2008195715A5 (es)
Jadhav et al. Peptide–drug conjugates as next-generation therapeutics: exploring the potential and clinical progress
CN109963620A (zh) 细胞靶向缀合物
ES2796053T3 (es) Nanomateriales multicomponentes de Au y métodos de síntesis
CN112156184B (zh) 靶向于egfr的抗体偶联药物、制备方法及应用
JP2022501313A (ja) 安定な濃厚放射性核種錯体溶液
CN113874051A (zh) 包含抗tm4sf1抗体的抗体-药物缀合物及其使用方法
TW202515620A (zh) 抗體－藥物偶聯物靶向治療前列腺癌和其他腫瘤
Sun et al. In vivo reversal of P-glycoprotein-mediated drug resistance in a breast cancer xenograft and in leukemia models using a novel, potent, and nontoxic epicatechin EC31
Chen et al. Oral Plant‐Derived Nanomedicines Mitigate Acetaminophen‐Induced Liver Injury by Modulating the Gut‐Liver Axis and Intestinal Microbiota Metabolism
Huang et al. Multimodal imaging-guided synergistic photodynamic therapy using carbonized Zn/Co Metal-organic framework loaded with cytotoxin against liver cancer
Damle Antibody-drug conjugates ace the tolerability test